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Significant heterogeneity of clinical presentation and disease progression exists within chronic obstructive
pulmonary disease (COPD). This article discusses and refines the concept of desaturator phenotypes in COPD with
pulmonary hypertension (PH) obtained by cluster analysis and presents a pattern of phenotypic markers that could
be used as a framework for future diagnosis and research. Nocturnal oxygen desaturation results in sleep
disturbances which predispose to nocturnal cardiac dysrhythmias, PH and possibly nocturnal death, particularly
during acute exacerbations. We assume that in patients with COPD at least two factors play a role in PH: the
severity of pulmonary impairment, and the severity of systemic nocturnal hypoxaemia due to reduced pulmonary
functions. Establishing a common language for future research will facilitate our understanding and management
of such a disease. This knowledge could lead to different pharmacological treatments and other interventions
directed at specific phenotypic groups.
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Introduction to COPD and its prevalence across the world
Chronic obstructive pulmonary disease (COPD) is char-
acterized by persistent airflow limitation that is usually
progressive and associated with an enhanced chronic in-
flammatory response in the airways and the lungs to
noxious particles or gases [1]. The World Health
Organization (WHO) has described COPD as a global
epidemic, and it is estimated that about 64 million
people worldwide are affected by this disease. In 2005
more than 3 million people died because of COPD,
accounting for 5% of all deaths worldwide that year. It is
estimated that the total number of deaths due to COPD
is likely to increase by over 30% in the next 10 years if
nothing is done to reduce the risks, particularly those
resulting from exposure to tobacco smoke [2]. No* Correspondence: d.torald@tin.it
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reproduction in any medium, provided the oreffective treatment for COPD exists to date and research
into new therapies will be essential if this disease is to be
managed in the future.
In recent years, it has emerged that COPD is a com-
plex disease with multiple clinical manifestations and
that COPD subjects cannot be described by the severity
of airflow limitation alone. Many other independent pre-
dictors of clinical outcome have been identified, includ-
ing worsening dyspnoea, frequency and severity of
exacerbations, malnutrition, depression and health-
related quality of life (HRQoL) impairment. Therefore,
one topic of growing interest in the scientific commu-
nity, highlighted by studies such as the ECLIPSE [3], is
the identification of different phenotypic subgroups of
patients. It is possible that the different phenotypes are
characterized by different etiopathogenetic mechanisms
and that patients in different subgroups will respond dif-
ferently to drug therapy.
This clinical commentary focuses on COPD and noc-
turnal hypoxaemia, which can be the cause of pulmonaryl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phenotype of COPD the desaturator characterized by
cluster analysis, a new method of statistical analysis. Clus-
ter analysis is used as artificial intelligence in such diverse
fields: biology, medicine, psychology, and business. It
entails grouping similar objects into distinct, mutually ex-
clusive subsets referred to as clusters. Elements within a
cluster share a high degree of “natural association”,
whereas the clusters are relatively distinct from one an-
other. This procedure has recently been used in clinical
medicine to classify patients and their data.
We assume that in patients with COPD and PH at
least two factors play a role: the severity of pulmonary
impairment, and the severity of nocturnal hypoxemia
due to reduced pulmonary functions. The severity of
COPD also influences the degree of oxygen desaturation
and the lower the FEV1/FVC ratio, the more likely is the
possibility of significant desaturation during sleep.Scientific knowledge on the issue
1) Epidemiological data suggest that nocturnal
symptoms and nocturnal oxygen desaturation with
symptomatic sleep disturbance are common and may
occur in more than 76% of patients with COPD.
2) COPD patients with a T90 of ≥ 30%, a mean
nocturnal arterial oxygen saturation (SatO2) of ≤ 90%
and a minimum (nadir) SatO2 of 85% have been
defined as desaturators (D) and the others as non-
desaturators (ND).
3) The worsening of nocturnal hypoxaemia is due to a
variable combination of alveolar hypoventilation and
ventilation-perfusion mismatching.
4) Nocturnal oxygen desaturation appears to contribute
to the development of pulmonary hypertension (PH).
PH is defined as an increase in mean pulmonary
arterial pressure (MPAP) ≥ 25 mmHg at rest as
assessed by right heart catheterization (RCH).
5) Poor correlation between lung function parameters
and pulmonary arterial pressure (PAP) suggests that
factors other than airway obstruction and loss of
alveolar surface area may play a role in PH.Main text
The complexity of COPD/COPD as a systemic disease
The recognition of COPD as a systemic disease has
developed in recent years [4]. Comorbidities such as
chronic heart failure, cardiovascular disease, depression,
diabetes, muscle wasting, weight loss, lung cancer, and
osteoporosis can frequently be found in patients with
COPD and are considered to be part of the commonly
prevalent non-pulmonary sequelae of the disease [5,6].
Systemic inflammation is considered a hallmark ofCOPD and may be one of the key mechanisms respon-
sible for the increased rate of comorbidities [7].
Even though more than 75% of patients with COPD
report poor sleep quality, night-time symptoms and
sleep disturbances in COPD are generally not considered
in the clinical management of the disease [8]. For in-
stance, the most recent Global Initiative for Chronic Ob-
structive Lung Disease guidelines (GOLD 2011) do not
mention sleep disturbance as a target for therapeutic
intervention, and no or very limited specific guidance is
offered on appropriate management strategies or
pharmacological interventions for patients with COPD
who report alterations in sleep. In fact, the nature and
cause of disturbed sleep in COPD has been poorly char-
acterized so far, and the long-term clinical consequences
of sleep disturbance in COPD have yet to be explored.
In general, COPD-associated PH is mild and develops
in patients with a severely impaired pulmonary function.
PH may develop slowly in the natural course of COPD.
The main cause is hypoxic vasoconstriction of small pul-
monary arterioles that subsequently undergo structural
changes, reducing their elasticity and cross-sectional sur-
face area [9]. Nocturnal hypoxaemia appears to contrib-
ute to the development of PH, even in the absence of
significant awake hypoxaemia [10].
Sleep disturbance and nocturnal oxygen desaturation
Sleep plays a key role in COPD, although the degree of
nocturnal oxygen desaturation during sleep varies from
patient to patient. Usually, in patients with COPD, there is
decreased sleep efficiency, decreased total sleep time, and
increased wake time after initial sleep onset. In addition,
there is decreased Rapid Eye Movement (REM) sleep and
decreased stages III and IV sleep. These changes in sleep
are more pronounced in elderly patients with COPD.
The nocturnal oxygen desaturation in COPD patients is
determined by the daytime arterial saturation. One study
[11] showed that, in COPD patients, breathing difficulties
during sleep are the most common symptoms after dys-
pnoea and fatigue [12]. Another study [13] confirmed a re-
duction in the amount and quality of sleep in COPD
patients compared with healthy controls. Patients with
COPD who are hypoxaemic during wakefulness become
more hypoxaemic during sleep [13]. The worsening of
nocturnal hypoxaemia is due to a variable combination
of alveolar hypoventilation and ventilation-perfusion
mismatching. The respiratory muscle contribution to
breathing is reduced in sleep, which results in a decreased
functional residual capacity (FRC) and, with a relative
increase in the physiological dead space, leads to hyper-
capnia and hence acidosis [14]. The consequences of
sleep-related hypoxaemia include peaks of PH due to hyp-
oxic pulmonary vasoconstriction, generally observed in
patients with marked daytime hypoxaemia [14] (Figure 1).
Figure 1 Pathophysiological effects of sleep on respiration in COPD patients with chronic nocturnal hypoxaemia.
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COPD during REM sleep, with associated oxygen desat-
uration [15]. A correlation has been shown between the
awake arterial oxygen tension (measured as the partial
pressure of oxygen in arterial blood (PaO2) in mmHg)
and nocturnal arterial oxygen desaturation (measured as
the percentage of oxygen saturation in arterial blood
(SatO2), particularly during REM sleep; in addition, the
nocturnal desaturation is accompanied by hypercapnia
[16,17]. The contribution of respiratory muscle hypo-
tonia to sleep-related breathing is reduced in sleep, par-
ticularly during REM. This contributes to a worsening of
ventilation-perfusion mismatching, which also aggra-
vates hypoxaemia and hypercapnia. The consequences of
nocturnal hypoxaemia (and hypercapnia) in patients
with COPD may include acute events, such as altered
sleep structure, arrhythmias and increased risk of cardio-
vascular and cerebrovascular disease [18].
Hypoxemia and COPD-associated pulmonary
hypertension
The exact prevalence of PH in patients with COPD is un-
clear [19], although it is more common and more severe
in patients with advanced COPD who show severe long-
term hypoxaemia. Even though PH is mild to moderatein most COPD patients, it can markedly worsen during
acute exacerbations, sleep and physical exercise, as
shown in a study by Kessler et al. [20] in which 25% of
COPD patients developed PH during physical activity.
These acute increases in PH can facilitate the develop-
ment of right heart failure (RHF), so it is important to
diagnose PH as soon as possible in high-risk COPD
patients. The diagnosis of PH in COPD patients is diffi-
cult. PH should be suspected in patients with COPD and
declining functional capacity or increasing shortness of
breath in the presence of stable airflow obstruction and
the lack of an alternative explanation (eg. interstitial lung
disease, obstructive sleep apnea, or other comorbidities).
The published studies differ not only in their definition
of PH but also in the conditions under which PH is
reported (rest, exercise and exacerbation). According to
the European Society of Cardiology and the European Re-
spiratory Society, PH is defined as an increase in mean
pulmonary arterial pressure (MPAP) ≥ 25 mmHg at rest as
assessed by right heart catheterization (RHC) [21]. This is
the definition adhered to by the authors of this commen-
tary. Nocturnal oxygen desaturation seems to contribute
to the development of PH, even in the absence of signifi-
cant daytime hypoxemia [22]. REM-associated falls in
SatO2 are associated with increases in pulmonary arterial
Figure 2 Correlation obtained by cluster analysis, between
mean pulmonary arterial pressures made by echocardiography
versus diurnal PaCO2 and nocturnal T90 values. (D) Desaturator
patients may be identified, by cluster analysis, by a pattern of Mean
PAP and, rather than by T90 alone, with the latter two variables
being predictors of nocturnal desaturation severity. From [35].
Toraldo et al. Multidisciplinary Respiratory Medicine 2012, 7:39 Page 4 of 7
http://www.mrmjournal.com/content/7/1/39pressure (PAP) which can be reversed by supplemental
oxygen, although most COPD patients with sustained PH
are also hypoxaemic during the daytime. Various arrhyth-
mias are also reported during episodes of nocturnal desat-
uration [23]. These consequences might help to explain
why nocturnal oxygen desaturation is a marker of
increased mortality, and why COPD patients are reported
to die more frequently at night than expected [24]. COPD
patients have increased circulating markers of systemic in-
flammation when compared with healthy controls [25].
Systemic inflammation stimulates pulmonary vasculature
and promotes the development of skeletal muscle dys-
function and osteopenia [26]. The pulmonary vasculature
of COPD patients with PH is characterized by luminal
narrowing due to thickening of the intima, along with ar-
teriolar muscularization.
Another major contributor to the development of PH
in COPD patients is nocturnal hypoxia-induced remodel-
ling of the pulmonary vasculature [27]. Hypoxia-induced
pulmonary vasoconstriction is a protective response that
keeps the ventilation-perfusion ratio optimal by shunting
blood away from hypoxemic areas. The traditional hyp-
oxic model of PH is based on the hypothesis that chronic
hypoxia initiates vascular remodelling leading to perman-
ent changes in pulmonary vasculature [28]. Studies per-
formed in vitro have elucidated the mechanisms
underlying hypoxia-driven vascular changes [29,30].
Barbera et al. [31] evaluated COPD patients undergoing
lung resection and demonstrated that vascular changes
contribute to vascular remodelling and may have an effect
on vascular dynamics leading to PH. Nocturnal hypoxia
may also induce endothelial cells to release proliferating
cytokines leading to cellular hypertrophy in the vessel wall
and an increase in the production of extracellular matrix
proteins [32]. Although one recent work [33] has shown
that there is no correlation between the severity of airway
obstruction hypoxemia and PH, there seems to be a large
body of evidence to support the role of hypoxemia-
induced remodelling of pulmonary vasculature in the de-
velopment of PH.
Discussion
In some studies [34-36], COPD patients have been categor-
ized as desaturators (D) or non-desaturators (ND) based
on the levels of oxygen desaturation defined by certain
parameters, namely SatO2 and T90. Nocturnal hypoxemia
has been defined as a SatO2 of ≤ 90% for at least 5 min
with a nadir SatO2 of ≤ 85%. The percentage of nocturnal
total recording time (TRT) has been defined as “time spent
in bed – sleep latency + intra-sleep wakefulness”. TRT with
a SatO2 of ≤ 90% has been defined as the T90 percentage.
The minimal TRT required for a satisfactory analysis of
nocturnal recordings was 2 hours. COPD patients with a
T90 of ≥ 30% and a nadir SatO2 of 85% have been definedas D patients and the others as ND patients. D patients are
more at risk of respiratory complications such as cardio-
vascular disease, hospitalization, and ultimately death [37].
In this commentary, the authors describe their own
studies in which cluster analysis was used to redefine the
COPD D phenotype and show that daytime clinical vari-
ables can be predictive of the severity of nocturnal oxy-
gen desaturation in D patients [34]. Cluster analysis
refers to the use of various algorithms to place indivi-
duals into different groups or “clusters”, based on mul-
tiple measured parameters, such that individuals in the
same cluster are more similar to each other than to
those in different clusters. In 29 out of 51 consecutive
COPD outpatients [22] with mild daytime hypoxemia
(PaO2 60–70 mmHg), cluster analysis identified a pat-
tern of daytime clinical variables that distinguished D
patients from ND patients. Considering all patients, the
values of T90, MPAP at rest, partial pressure of CO2 in
the blood (PaCO2), nadir nocturnal SatO2, mean noctur-
nal SatO2 level, predicted total lung capacity (TLC),
baseline awake SatO2 level, predicted vital capacity (VC),
and body mass index (BMI) had a bimodal distribution.
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tween men and women. Rather than using T90 alone,
the study showed that D patients may be identified by a
pattern of T90 (30.08%–45.1%, P = 0.0001), MPAP (33.1
± 0.7 mmHg, P = 0.0006), and PaCO2(35.0–57.9 mmHg,
p = 0.0005) values, with the latter two variables being pre-
dictors of the severity of nocturnal oxygen desaturation.
Cluster analysis has also identified a subgroup of COPD
D patients in which parameters describing PH and para-
meters describing respiratory dysfunction are linked.
These data also correlate with BMI, PaCO2, VC and TLC.
In which case, the parameters describing respiratory dys-
function (PaCO2, VC, TLC) and BMI could be used to
predict PH. Our recent article [38] defined the COPD D
phenotype with PH as a new disease phenotype (Figure 2).
In contrast, Chaouat and co-workers [39] showed that
isolated nocturnal hypoxaemia does not induce perman-
ent PH, nor leads to worsening levels of daytime blood
gases. In fact, it is now recognized that the development
of PH due to chronic nocturnal hypoxaemia requires a
certain threshold of severity and duration. It is likely that
this threshold was not reached during the episodes of
nocturnal hypoxaemia in D patients this study.Figure 3 Biological mechanisms for the development of pulmonary h
that drive vasoconstriction, vasodilation, and cell proliferation in the walls oFinally, some studies [40,41] have focused on the role of
the alteration of the pulmonary vessels in the development
of PH. Hypoxic pulmonary vasoconstriction (HPV) is a
physiological self-regulatory response to alveolar hypoxia
that distributes pulmonary capillary blood flow to areas of
high oxygen availability. This principle is known as the
von Euler–Liljestrand mechanism and serves to optimize
the flow of blood in the pulmonary capillaries. The alter-
ation of this mechanism may result in hypoxaemia. Under
conditions of chronic hypoxia, generalized vasoconstric-
tion of the pulmonary vasculature in concert with noctur-
nal hypoxia-induced vascular remodelling leads to PH.
Reactive oxygen species, redox couplet and adenosine
monophosphate-activated kinases are under investigation
as mediators of HPV. In addition, experimental data have
suggested that several inflammatory proteins play an im-
portant role in pulmonary artery physiology and in the
regulation of pulmonary artery pressure. However, only a
portion of the pathways essential for HPV have been iden-
tified and there are still plenty of questions to answer be-
fore a complete picture of the oxygen sensing and signal
transduction mechanisms of this important physiological
response can be elucidated [42] (Figure 3).ypertension in COPD patients. The Diagram shows various processes
f the small pulmonary arteries.
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Patients with COPD frequently experience nocturnal
oxygen desaturation episodes, leading to nocturnal hyp-
oxemia. Chronic nocturnal hypoxemia contributes to the
development of an adverse sequelae of COPD, including
PH, skeletal muscle dysfunction, and cardiovascular dis-
ease. Subsequently, the concept of chronic inflammation
as one of the key factors involved in pulmonary vascular
remodeling has emerged. We propose that data from
large clinical trials should be re-analyzed using cluster
analysis in order to classify patients according to their
clinical characteristics at study entry. However, the clin-
ical application of cluster analysis will depend on devel-
oping diagnostic criteria to allow new individuals to be
allocated to pre-established clusters. Only time will tell if
this new approach is effective in the prediction or diag-
nosis of COPD-associated diseases and in their preven-
tion or treatment respectively.
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